Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Ernexa Therapeutics appointed Dr. Robert J. Spiegel, a former Schering-Plough Chief Medical Officer with 25+ years in oncology drug development, to its Board of Directors. The appointment comes as Ernexa targets an IND submission for lead program ERNA-101 in Q4 2026, with a first-in-human study in platinum-resistant ovarian cancer planned for Q1 2027.
Key figures
- Drug Name
- ERNA-101
- Preclinical result
- complete tumor clearance and 100% survival in ovarian cancer model with anti-PD-1 combination
- Ind submission target
- Q4 2026
- First in human study start
- Q1 2027
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.